PAG1抗体—艾普蒂

+ +

•  

   

     IHC-P analysis of tonsil tissue by PAG1 antibody (P15825) IHC-P was performed using sections of the formalin-fixed paraffin-embedded tonsil tissue;Result: Germinal center and non-germinal center cells are positively stained at the cell membrane.    

  
  

The PAG1 (Phosphoprotein Associated with Glycosphingolipid-enriched microdomains 1) antibody is a tool used to study the PAG1 protein, a transmembrane adaptor protein implicated in cellular signaling regulation. PAG1. also known as Csk-binding protein (Cbp), is enriched in lipid rafts and serves as a scaffold to recruit signaling molecules, particularly in immune cells. It interacts with C-terminal Src kinase (Csk), which inhibits Src family kinases (SFKs) by phosphorylating their inhibitory tyrosine residues. This mechanism modulates T-cell receptor (TCR) and B-cell receptor (BCR) signaling, maintaining immune homeostasis by balancing activation and inhibition.

Research using PAG1 antibodies has revealed its dual role in cancer and autoimmune diseases. In some cancers, PAG1 overexpression suppresses SFK activity, potentially inhibiting metastasis, while its downregulation may enhance oncogenic signaling. Conversely, in autoimmune disorders like multiple sclerosis, reduced PAG1 expression correlates with hyperactive T-cell responses. Antibodies against PAG1 enable detection of its expression patterns, post-translational modifications (e.g., phosphorylation), and interactions in pathways involving SFKs, Csk, or ubiquitin ligases. Commercial PAG1 antibodies are widely used in Western blotting, immunohistochemistry, and co-immunoprecipitation studies. However, researchers must validate antibody specificity due to potential cross-reactivity with homologous proteins. Ongoing studies explore PAG1's therapeutic potential as a biomarker or target in immune regulation and cancer.